AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
Every time Kyle publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback